These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26259734)

  • 21. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
    Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
    Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune cell regulation of glia during CNS injury and disease.
    Greenhalgh AD; David S; Bennett FC
    Nat Rev Neurosci; 2020 Mar; 21(3):139-152. PubMed ID: 32042145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of viral and self-antigens by T
    Paroni M; Maltese V; De Simone M; Ranzani V; Larghi P; Fenoglio C; Pietroboni AM; De Riz MA; Crosti MC; Maglie S; Moro M; Caprioli F; Rossi R; Rossetti G; Galimberti D; Pagani M; Scarpini E; Abrignani S; Geginat J
    J Allergy Clin Immunol; 2017 Sep; 140(3):797-808. PubMed ID: 28237728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of autoimmune CNS inflammation by astrocytes.
    Rothhammer V; Quintana FJ
    Semin Immunopathol; 2015 Nov; 37(6):625-38. PubMed ID: 26223505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-modifying agents do not impair the survival, migration or proliferation of oligodendrocyte progenitors (CG-4) in vitro.
    Halfpenny CA; Scolding NJ
    J Neuroimmunol; 2003 Jun; 139(1-2):9-16. PubMed ID: 12799015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment for multiple sclerosis in patients with collagen diseases].
    Kohriyama T; Ochi K
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():234-40. PubMed ID: 26480706
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The need for a new strategy for the treatment of multiple sclerosis.
    Davison AN
    J Neurol; 1988 Jul; 235(6):327-9. PubMed ID: 3171613
    [No Abstract]   [Full Text] [Related]  

  • 31. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Astrocytes in multiple sclerosis.
    Ludwin SK; Rao VTs; Moore CS; Antel JP
    Mult Scler; 2016 Aug; 22(9):1114-24. PubMed ID: 27207458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
    Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
    PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain-immune connection: immuno-regulatory properties of CNS-resident cells.
    Becher B; Prat A; Antel JP
    Glia; 2000 Feb; 29(4):293-304. PubMed ID: 10652440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis research: diagnostics, disease-modifying treatments, and emerging therapies.
    Costello K
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S14-23. PubMed ID: 24217187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation.
    Cannella B; Raine CS
    Ann Neurol; 2004 Jan; 55(1):46-57. PubMed ID: 14705111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of cholera toxin B subunit: a surface marker for murine microglia but not oligodendrocytes or astrocytes.
    Nedelkoska L; Benjamins JA
    J Neurosci Res; 1998 Sep; 53(5):605-12. PubMed ID: 9726431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.